PetMed Express (NASDAQ:PETS) is set to post its quarterly earnings results on Monday, January 22nd. Analysts expect PetMed Express to post earnings of $0.31 per share for the quarter.
PetMed Express (NASDAQ:PETS) last posted its earnings results on Monday, October 23rd. The company reported $0.43 EPS for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.13. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. The business had revenue of $66.70 million for the quarter, compared to analysts’ expectations of $63.41 million. During the same quarter in the previous year, the firm earned $0.24 earnings per share. The business’s revenue was up 9.7% compared to the same quarter last year. On average, analysts expect PetMed Express to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of PetMed Express (PETS) opened at $52.94 on Monday. PetMed Express has a 52-week low of $19.21 and a 52-week high of $53.32. The company has a market capitalization of $1,090.00, a PE ratio of 35.53, a PEG ratio of 3.15 and a beta of 1.12.
In related news, Director Ronald J. Korn sold 1,000 shares of the business’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $35.57, for a total value of $35,570.00. Following the transaction, the director now owns 73,833 shares in the company, valued at approximately $2,626,239.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gian Fulgoni sold 20,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the transaction, the director now owns 55,900 shares in the company, valued at approximately $2,480,842. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.
A number of analysts have recently commented on the company. ValuEngine cut PetMed Express from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Credit Suisse Group reiterated an “underperform” rating and set a $19.00 target price on shares of PetMed Express in a research report on Monday, October 2nd. Northcoast Research set a $58.00 target price on PetMed Express and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research cut PetMed Express from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 25th. Finally, BidaskClub upgraded PetMed Express from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. PetMed Express presently has a consensus rating of “Hold” and a consensus price target of $42.80.
WARNING: “PetMed Express (PETS) to Release Earnings on Monday” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/15/petmed-express-pets-to-release-earnings-on-monday.html.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.